ESTRO 2024 - Abstract Book

S1909

Clinical - Mixed sites, palliation

ESTRO 2024

Treatment was generally well tolerated. Only 8 patients (19.5%) experienced some kind of acute toxicity, no G3 or G4 toxicity was recorded. Most common side effects was thoracic pain G1 (4 patients) or G2 (2 patients). One patient experienced esophagitis G2, while one other cough and dyspnoea G1. Late toxicity profile was good with chronic pain reported by 4 patients (two G1, one G2 and one G3). No other late side effect was recorded.